Abstract
Background: South African von Willebrand disease (VWD) care is challenged by the lack of laboratory testing standardisation, lack of national clinical guidelines, limited undergraduate exposure to bleeding disorders and limited pharmacological resources. As the only reference testing facility performing VWD confirmatory testing, our experience in the diagnosis of the majority of VWD cases in South Africa has highlighted many areas where improvements are desperately needed. Methods: We conductedd a retrospective audit of 250 VWD cases at our laboratory where we calculated the percentage misdiagnoses should only the von Willebrand factor (VWF) levels and the ristocetin cofactor activity assays be used. Results: We have shown that performing a limited panel of VWD testing (VWF antigen and ristocetin cofactor activity only) could lead to the misdiagnosis of VWD in up to 77% of cases analysed at our laboratory. If the multimeric analysis was to be included in the diagnostic setup, together with the limited panel, still 20% of patients would be misdiagnosed. The underdiagnosis and under-reporting of VWD greatly underestimates the burden of the disease and the impact on the healthcare system. Conclusions: Future advancements in VWD care in South Africa should be focused on correcting these shortcomings.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.